DT Investment Partners LLC trimmed its position in shares of The Chemours Company (NYSE:CC – Free Report) by 70.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,561 shares of the specialty chemicals company’s stock after selling 6,204 shares during the period. DT Investment Partners LLC’s holdings in Chemours were worth $35,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of CC. FNY Investment Advisers LLC acquired a new stake in shares of Chemours in the 1st quarter valued at approximately $27,000. UMB Bank n.a. boosted its stake in shares of Chemours by 73.9% in the 1st quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company’s stock valued at $30,000 after purchasing an additional 948 shares in the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Chemours by 100.4% in the 4th quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company’s stock valued at $38,000 after purchasing an additional 1,119 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company’s stock valued at $30,000 after purchasing an additional 1,444 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Chemours in the 4th quarter valued at approximately $48,000. 76.26% of the stock is currently owned by institutional investors and hedge funds.
Chemours Stock Down 0.0%
Shares of NYSE CC opened at $12.73 on Friday. The company has a 50 day simple moving average of $11.27 and a 200 day simple moving average of $14.10. The firm has a market cap of $1.90 billion, a PE ratio of 63.63 and a beta of 1.65. The Chemours Company has a 1 year low of $9.13 and a 1 year high of $25.54. The company has a debt-to-equity ratio of 7.01, a current ratio of 1.75 and a quick ratio of 0.83.
Chemours Announces Dividend
The company also recently declared a dividend, which was paid on Monday, June 16th. Shareholders of record on Monday, May 19th were issued a dividend of $0.0875 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a yield of 3.17%. Chemours’s payout ratio is 175.00%.
Insider Activity at Chemours
In other news, insider Damian Gumpel purchased 13,400 shares of the stock in a transaction on Monday, June 2nd. The stock was purchased at an average price of $9.22 per share, for a total transaction of $123,548.00. Following the acquisition, the insider owned 123,879 shares in the company, valued at $1,142,164.38. This trade represents a 12.13% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Shane Hostetter purchased 4,450 shares of the stock in a transaction on Monday, May 19th. The shares were purchased at an average price of $11.28 per share, with a total value of $50,196.00. Following the acquisition, the chief financial officer owned 59,694 shares in the company, valued at approximately $673,348.32. The trade was a 8.06% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 25,672 shares of company stock valued at $251,573. Company insiders own 0.47% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have recently weighed in on the stock. UBS Group reduced their price target on shares of Chemours from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Royal Bank Of Canada raised their price target on shares of Chemours from $14.00 to $15.00 and gave the company an “outperform” rating in a research note on Thursday. Truist Financial reduced their price target on shares of Chemours from $27.00 to $22.00 and set a “buy” rating on the stock in a research note on Monday, April 14th. Barclays dropped their price objective on shares of Chemours from $16.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, May 28th. Finally, Morgan Stanley dropped their price objective on shares of Chemours from $22.00 to $15.00 and set an “equal weight” rating for the company in a report on Monday, May 12th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $17.33.
Get Our Latest Analysis on Chemours
About Chemours
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Featured Stories
- Five stocks we like better than Chemours
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- MarketBeat Week in Review – 06/30 – 07/04
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- The Apple Comeback Will Be Better Than the Setback
- What is a SEC Filing?
- How a Government Loan Changes the Game for Plug Power
Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Chemours Company (NYSE:CC – Free Report).
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.